The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer
暂无分享,去创建一个
Zhong-xin Huang | Jinbang Li | X. Lyu | Lujia Chen | Guangyu Yao | Xiaolei Hu | Yahong Cai | Wenji Li | Xin Li | Changsheng Ye | Changsheng Ye | Lujia Chen | Xin Li | Jinbang Li | Zhongxi Huang | Guangyu Yao | Xiaoming Lyu | Xiaolei Hu | Yahong Cai | Wenji Li
[1] G. Vlastos,et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001. , 2005, European journal of cancer.
[2] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] A. Jemal,et al. Global Cancer Statistics , 2011 .
[4] Gordon Stamp,et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.
[5] Stefan Michiels,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Seed,et al. A PCR primer bank for quantitative gene expression analysis. , 2003, Nucleic acids research.
[7] N. Longo,et al. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma , 2005, International journal of cancer.
[8] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[9] Rakesh K. Singh,et al. CXCL8 and its cognate receptors in melanoma progression and metastasis. , 2010, Future oncology.
[10] Ku-Sang Kim,et al. Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort , 2013, Breast Cancer Research and Treatment.
[11] Yuntao Xie,et al. BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer , 2009, Breast Cancer Research and Treatment.
[12] S. Narula,et al. Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. , 2001, Cytokine.
[13] V. Pistoia,et al. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow , 2008, Cancer Immunology, Immunotherapy.
[14] J. Rodriguez-Sierra,et al. Younger women with breast carcinoma have a poorer prognosis than older women , 1996, Cancer.
[15] J. Blay,et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.
[16] A. Jauch,et al. Breast cancer in young women (≤35 years): Genomic aberrations detected by comparative genomic hybridization , 2003, International journal of cancer.
[17] Yan Zhou,et al. The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. , 2005, Carcinogenesis.
[18] L. Coussens,et al. Lymphocytes in cancer development: polarization towards pro-tumor immunity. , 2010, Cytokine & growth factor reviews.
[19] V. Malhotra,et al. CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis , 2013, Breast Cancer Research and Treatment.
[20] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] G. Hortobagyi,et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis , 2001, Cancer.
[22] T. Naab,et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. , 2007, The Journal of surgical research.
[23] J. Marks,et al. Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors , 2008, PloS one.
[24] S. Ahn,et al. Do Very Young Korean Breast Cancer Patients Have Worse Outcomes? , 2007, Annals of Surgical Oncology.
[25] C. Bokemeyer,et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients , 2008, British Journal of Cancer.
[26] V. Malhotra,et al. Erratum to: CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis , 2016, Breast Cancer Research and Treatment.
[27] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] R. Strieter,et al. CXC chemokines in cancer angiogenesis and metastases. , 2010, Advances in cancer research.
[29] B. Sipos,et al. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. , 2006, Cancer research.
[30] A. Jemal,et al. Breast cancer statistics, 2013 , 2014, CA: a cancer journal for clinicians.
[31] A. Zlotnik. Chemokines in neoplastic progression. , 2004, Seminars in cancer biology.
[32] F. Balkwill. Cancer and the chemokine network , 2004, Nature Reviews Cancer.
[33] C. Shapiro,et al. Trends in breast cancer presentation and care according to age in a single institution. , 2004, American journal of surgery.
[34] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Ghaderi,et al. Chemokine and chemokine receptors: a comparative study between metastatic and nonmetastatic lymph nodes in breast cancer patients. , 2012, European cytokine network.
[36] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[37] Molin Wang,et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] F. Carvalho,et al. Triple‐negative breast carcinomas are a heterogeneous entity that differs between young and old patients , 2010, Clinics.
[39] H. Saji,et al. Significant correlation of monocyte chemoattractant protein‐1 expression with neovascularization and progression of breast carcinoma , 2001, Cancer.
[40] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] L BenitezSoto. Breast cancer statistics , 1954 .
[42] J. Stec,et al. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. , 2005, Endocrine-related cancer.
[43] A. Ben-Baruch,et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. , 1999, Cancer research.
[44] Hai Zhang,et al. GenCLiP 2.0: a web server for functional clustering of genes and construction of molecular networks based on free terms , 2014, Bioinform..
[45] M. Friedlander,et al. Breast cancer in young women and its impact on reproductive function , 2009, Human reproduction update.
[46] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[47] David M. Thomas,et al. The distinctive biology of cancer in adolescents and young adults , 2008, Nature Reviews Cancer.
[48] P. Dhawan,et al. Role of CXCL1 in tumorigenesis of melanoma , 2002, Journal of leukocyte biology.
[49] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[50] L Collette,et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? , 2003, European journal of cancer.
[51] M. Bonnen,et al. The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is "young"? , 2006, International journal of radiation oncology, biology, physics.
[52] R. Myers,et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.
[53] P. Johnson,et al. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells , 2010, Molecular Cancer.
[54] A. Luini,et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] Benjamin Haibe-Kains,et al. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.
[56] P. Johnston,et al. Nonapical and Cytoplasmic Expression of Interleukin-8, CXCR1, and CXCR2 Correlates with Cell Proliferation and Microvessel Density in Prostate Cancer , 2005, Clinical Cancer Research.
[57] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[58] H. Saji,et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] J. Marks,et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Jin Zhao,et al. GenCLiP: a software program for clustering gene lists by literature profiling and constructing gene co-occurrence networks related to custom keywords , 2008, BMC Bioinformatics.
[61] Yan Zhou,et al. The chemokine GRO-α (CXCL1) confers increased tumorigenicity to glioma cells , 2005 .
[62] I. Smith,et al. Breast cancer in adolescents and young women. , 2003, European journal of cancer.
[63] N. Pavlidis,et al. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. , 2012, Clinical breast cancer.
[64] M. Keating,et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. , 2007, Blood.
[65] J. Bergh,et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis , 2013, Genome Biology.
[66] I. Bleiweiss,et al. Stage 0 to stage III breast cancer in young women. , 2000, Journal of the American College of Surgeons.
[67] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[68] E. Nice,et al. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection , 2013, Journal of Translational Medicine.
[69] G. Stamp,et al. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. , 1997, The American journal of pathology.
[70] G. Stamp,et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. , 1995, The Journal of clinical investigation.
[71] Jason G. Cyster,et al. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1 , 1998, Nature.
[72] P. Andersen,et al. Factors influencing the effect of age on prognosis in breast cancer: population based study , 2000, BMJ : British Medical Journal.
[73] A. Darzi,et al. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer , 2007, Clinical & Experimental Metastasis.
[74] A. Bleyer,et al. Breast cancer before age 40 years. , 2009, Seminars in oncology.
[75] M. Baggiolini,et al. B Cell–attracting Chemokine 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via BLR1/CXCR5 , 1998, The Journal of experimental medicine.
[76] Rohaizak Muhammad,et al. Gene expression patterns distinguish breast carcinomas from normal breast tissues: the Malaysian context. , 2010, Pathology, research and practice.
[77] A. Hutcheon,et al. Breast cancer in women aged 35 and under: prognosis and survival. , 2002, Journal of the Royal College of Surgeons of Edinburgh.
[78] Wanjun Chen,et al. Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression , 2011, International journal of biological sciences.
[79] Vivek Aggarwal,et al. Spectrum of Breast Cancer in Asian Women , 2007, World journal of surgery.